buy ptd

If you want to buy a biotech stock why not this one, it is the most undervalued stock in the sector, the carhts looks good and it has good fundamentals, this one could head back to $2 before you know it.

Huntleys' Recommendation


Last Analyst Update: 09/06/2004
Recommendation Speculative Buy
Last Price 1.46
Market Cap 236
Sector Pharmaceuticals & Biotechnology


Rating Outlook
What a mess, since the announcement of the merger there has been a deterioration of share holder value for both companies. PTD is the favored stock with $39m of cash in the bank and represents leverage on the outcome of the J&J dispute. After speaking with Executive Chairman Mel Bridges we now expect the arbitration to be settled at the end of 4Q CY04, around Christmas. The merger made perfect sense to both companies but in light of current events we would suggest investors hold AGX and buy PTD. AGX we would hold pending the release of efficacy data from its Phase 2 trial for Thromboview. PTD has financial capacity, experienced management and leverage to earnings with a resolution of the J+J arbitration.